A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.



Eligible Ages
Over 18 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Eastern Collaborative Oncology Group (ECOG) performance score of less than or equal to 2. - Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is refractory to the most recent line of therapy. - Positive for translocation t(11;14) as determined by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing. - Received prior treatment with at least 1 prior line of therapy for MM. - Measurable disease on Screening per International Myeloma Working Group (IMWG) criteria. - Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within 2 weeks prior to first dose of study drug.

Exclusion Criteria

  • Has a pre-existing condition that is contraindicated including. - Non-secretory or oligo-secretory MM - Active plasma cell leukemia. - Waldenström's macroglobulinemia. - Primary amyloidosis. - POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes). - Active hepatitis B or C infection based on screening blood testing. - Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. - Significant cardiovascular disease. - Major surgery within 4 weeks prior to first dose. - Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days prior to first dose. - Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first dose. - Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose. - Any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study. - History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry Other protocol defined inclusion/exclusion criteria could apply

Study Design

Phase 2
Study Type
Intervention Model
Single Group Assignment
Primary Purpose
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Venetoclax + Carfilzomib + Dexamethasone
Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 18 participants. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 additional participants. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy. Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 7 additional participants. Part 4, An additional 65 participants t(11;14) positive will receive varying doses of the VenKd combination or carfilzomib and dexamethasone
  • Drug: Carfilzomib
    Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing. Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16. Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16. Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16.
    Other names:
    • Kyprolis
  • Drug: Venetoclax
    Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
    Other names:
    • Venclexta
    • ABT-199
  • Drug: Dexamethasone
    Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.

Recruiting Locations

University of Alabama at Birmingham - Main /ID# 151405
Birmingham, Alabama 35233

University of Arkansas for Medical Sciences /ID# 151399
Little Rock, Arkansas 72205

Memorial Healthcare System /ID# 224862
Hollywood, Florida 33021-3513

Emory University, Winship Cancer Institute /ID# 161710
Atlanta, Georgia 30322

The University of Chicago Medical Center /ID# 151395
Chicago, Illinois 60637-1443

Indiana Blood & Marrow Transpl /ID# 218862
Indianapolis, Indiana 46237

Central Maine Medical Center /ID# 218856
Lewiston, Maine 04240

Washington University-School of Medicine /ID# 222651
Saint Louis, Missouri 63110

Oncology Hematology Associates (OHA) - Springfield /ID# 218855
Springfield, Missouri 65807-5287

Duke Cancer Center /ID# 162062
Durham, North Carolina 27710-3000

University of Pennsylvania /ID# 151768
Philadelphia, Pennsylvania 19104-5502

University of Texas Southwestern Medical Center /ID# 218336
Dallas, Texas 75390-7208

Baylor Scott & White Medical Center- Temple /ID# 218252
Temple, Texas 76508-0001

University of Utah /ID# 151397
Salt Lake City, Utah 84112-5500

Aurora Health Care, Aurora Cancer Center /ID# 209612
Wauwatosa, Wisconsin 53226-3436

Auxilio Mutuo Cancer Center /ID# 157853
San Juan, Puerto Rico 00918

VA Caribbean Healthcare System /ID# 157854
San Juan, Puerto Rico 00921-3201

More Details


Study Contact



Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.